


D'HUART Elise^{1,2}, SACREZ Matthieu^{1,2}, SOBALAK Nathalie¹, VIGNERON Jean^{1,2}, DEMORE Béatrice^{1,2,3}.
 1 : Pharmacie à Usage Intérieur, Hôpitaux de Brabois, 54511 Vandœuvre-lès-Nancy, France.
 2 : Infotab, non-profit association, Heillecourt, France
 3 : Université de Lorraine, EA 4360 APEMAC, Nancy, France.

Introduction

Cabazitaxel is an antineoplastic agent, indicated, in combination with prednisone or prednisolone, for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen.

To our knowledge, few studies have been published on the stability of cabazitaxel in infusion bags. The Stabiis® database has selected a study demonstrating the stability of this molecule at 0.15 mg/mL for 28 days at 4°C and 25°C in polyolefin bags¹.

¹ Lazzarini R et al. Physicochemical stability of cabazitaxel and docetaxel solutions. EJHP 2014 ;22:150-15.



Objectives

Physicochemical stability study of **Cabazitaxel Zentiva®** solutions :

1		20 mg/mL vials after opening with a SPIKE device	∅	25°C	Day 0, 14 and 28
2		0.1 and 0.26 mg/mL in three types of infusion bags ^{2,3,4}	NaCl 0.9% D5W	2-8°C ² 25°C ^{3,4}	

² **Freeflex®** : polypropylene multilayers
³ **Viaflo®** : multilayer high density polyethylene, polyamide, polypropylene
⁴ **Easylex®** : polyolefin

D5W : dextrose 5% in water

Materials and methods

Chemical stability

- Method** : RP-HPLC with DAD detector at 232 nm¹
 - C18 LiCrospher® 12.5 cm, particule size= 3.5 µm
 - Mobile phase** : isocratic mode : 42% of water for chromatography, 32% of methanol and 26% of acetonitrile
 - Flow rate** : 1.2 mL/min **Injection volume**: 25 µL
- Validation of analytical method** as recommended by ICH Q2(R1)
 - Forced degradation** to evaluate **stability indicating capability**

ACIDIC DEGRADATION	ALKALINE DEGRADATION	PHOTOLYTIC DEGRADATION
HCl – 1.69 M 10 min	NaOH – 0.05 M 1 min	24 h

- Linearity** : standard curve with 5 points : 50 – 400 µg/mL
- Repeatability and intermediate precision** : 3-point measurement (100, 200 and 300 µg/mL)
- Specificity**


2. **pH measurements (Crison pH25 pHmeter)** : for each infusion bags

Acceptance criteria ± 10% of initial concentration and no visual or significant pH value modification

Physical stability

- Visual examination** : change of colour, precipitation, gaz formation

Study design




- Analysis by RP-HPLC** : concentrations and degradations products (n=1/bag ; n=3/vial)
- pH measurements** for infusion bags
- Visual examination** for each condition

Results

1. Validation of the method

- Linearity** : R² > 0.9997
- Repeatability** : [0.43-1.15%]
- Intermediate precision** : [0.82-1.65%]
- Retention time** : 9.5 min
- Stability indicating capability** :



Chromatogram of cabazitaxel solution at 200 µg/mL after alkaline degradation (NaOH 0.05 M, 1 min)

2. B. Chemical stability in infusion bags pH values


- No modification : maximum variation at D14 : 0.39 pH unit and 0.24 at D28

3. Physical stability

- No visual modification

2. A. Chemical stability - HPLC analysis

- Infusion bags** : average of the 3 bags per condition



Conclusion

Cabazitaxel Zentiva® 20 mg/mL vials with a SPIKE were physically and chemically **stable for 28 days at 25°C**, allowing the remainder of the vial to be used over several days.

Cabazitaxel Zentiva® solutions diluted at 0.1 and 0.26 mg/mL in NaCl 0.9% or in D5W were physically and chemically **stable for 28 days at 2-8°C** in Freeflex® infusion bags or **25°C** in Viaflo® and Easylex® infusion bags, allowing preparations in advance.